Navigating Post–CAR T Progression: Therapy Selection and Targeting
Panelists discuss how sequential B-cell maturation agent (BCMA)–targeting therapies can be effective despite potential resistance patterns, with experts evaluating factors like prior response duration, alternative targets like GPRC5D or FcRH5, and patient-specific characteristics when deciding treatment sequencing after CAR T progression.
Video content above is prompted by the following:
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR T therapies?
- When would you consider switching to a therapy hitting a different target?
- Describe your approach to treatment sequencing if a patient had received CAR T-cell therapy before bispecifics and progresses.
- Which therapies might you consider and why?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
